https://scholars.lib.ntu.edu.tw/handle/123456789/487326
標題: | Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma | 作者: | Chiang C.-T. Yeh P.-Y. Gao M. Chen C.-W. Yeh L.-C. Feng W.-C. SUNG-HSIN KUO CHIH-HUNG HSU YEN-SHEN LU ANN-LII CHENG |
公開日期: | 2010 | 卷: | 298 | 期: | 2 | 起(迄)頁: | 195-203 | 來源出版物: | Cancer Letters | 摘要: | Single-agent mammalian target of rapamycin complex 1 (mTORC1) inhibitors have recently been reported as effective salvage treatment in non-Hodgkin lymphoma (NHL). The combined effect of mTORC1 inhibitor, RAD001, with chemotherapeutic agents used for relapsed or refractory NHL was examined. Synergistic interactions were observed for RAD001 plus gemcitabine or paclitaxel in six NHL cell lines; enhanced gemcitabine- and paclitaxel-induced caspase-dependent apoptosis associated with down-regulation of mTOR signaling was detected. Synergistic interactions were also observed with RAD001 plus gemcitabine and paclitaxel. In conclusion, synergistic cytotoxicity was observed with RAD001 plus gemcitabine and paclitaxel in NHL cells. Combination therapy with these three drugs should be examined in patients with refractory or relapsed NHL. ? 2010 Elsevier Ireland Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77957938917&doi=10.1016%2fj.canlet.2010.07.005&partnerID=40&md5=431a086fcd8655f7cc4f40b7dd87441f https://scholars.lib.ntu.edu.tw/handle/123456789/487326 |
ISSN: | 0304-3835 | DOI: | 10.1016/j.canlet.2010.07.005 | SDG/關鍵字: | benzyloxycarbonylvalylalanylaspartyl fluoromethyl ketone; caspase; everolimus; gemcitabine; mammalian target of rapamycin; navelbine; paclitaxel; protein mcl 1; apoptosis; article; cancer cell culture; cancer combination chemotherapy; cell survival; cell viability; controlled study; cytotoxicity; down regulation; drug antagonism; drug potentiation; drug sensitization; enzyme activation; fluorescence activated cell sorting; human; human cell; IC 50; leukemia cell line; nonhodgkin lymphoma; priority journal; protein expression; signal transduction; Western blotting; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoma, Non-Hodgkin; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Mammalia |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。